Levosimendan is a calcium-sensitizing drug with inotropic and other properties that may improve outcomes in patients with sepsis

[1]  G. Perkins,et al.  Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial. , 2016, JAMA.

[2]  Christopher W Seymour,et al.  Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[3]  R. Bellomo,et al.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[4]  G. Gulati,et al.  Detection of Myocardial Dysfunction in Septic Shock: A Speckle-Tracking Echocardiography Study , 2015, Anesthesia and analgesia.

[5]  N. Matsuda,et al.  Anti-Inflammatory Profile of Levosimendan in Cecal Ligation-Induced Septic Mice and in Lipopolysaccharide-Stimulated Macrophages* , 2015, Critical care medicine.

[6]  A. Zangrillo,et al.  Levosimendan reduces mortality in patients with severe sepsis and septic shock: A meta-analysis of randomized trials. , 2015, Journal of critical care.

[7]  G. Perkins,et al.  An efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS): protocol for a randomized controlled trial , 2014, Trials.

[8]  Claude Guerin,et al.  High versus low blood-pressure target in patients with septic shock. , 2014, The New England journal of medicine.

[9]  G. Perkins,et al.  The Interaction of Vasopressin and Corticosteroids in Septic Shock: A Pilot Randomized Controlled Trial* , 2014, Critical care medicine.

[10]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[11]  M. Singer,et al.  Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. , 2013, JAMA.

[12]  M. Nieminen,et al.  Levosimendan: current data, clinical use and future development , 2013, Heart, lung and vessels.

[13]  C. Sprung,et al.  Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012 , 2013, Intensive Care Medicine.

[14]  A. Gordon,et al.  The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. , 2012, Chest.

[15]  M. Inal,et al.  The effects of levosimendan vs dobutamine added to dopamine on liver functions assessed with noninvasive liver function monitoring in patients with septic shock. , 2012, Journal of critical care.

[16]  John A Kellum,et al.  Design of clinical trials in acute kidney injury: report from an NIDDK workshop on trial methodology. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[17]  M. Dünser,et al.  Adverse cardiac events during catecholamine vasopressor therapy: a prospective observational study , 2012, Intensive Care Medicine.

[18]  M. Joannidis,et al.  Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: a prospective observational study , 2011, Critical care.

[19]  C. Ince,et al.  Levosimendan for resuscitating the microcirculation in patients with septic shock: a randomized controlled study , 2010, Critical care.

[20]  E. Ruokonen,et al.  Association of arterial blood pressure and vasopressor load with septic shock mortality: a post hoc analysis of a multicenter trial , 2009, Critical care.

[21]  R. Dellinger.  Actual incidence of global left ventricular hypokinesia in adult septic shock , 2009 .

[22]  L. Opie,et al.  A role for the RISK pathway and KATP channels in pre‐ and post‐conditioning induced by levosimendan in the isolated guinea pig heart , 2008, British journal of pharmacology.

[23]  Sangeeta Mehta,et al.  Vasopressin versus norepinephrine infusion in patients with septic shock. , 2008, The New England journal of medicine.

[24]  O. Bech-Hanssen,et al.  Effects of Levosimendan on Left Ventricular Relaxation and Early Filling at Maintained Preload and Afterload Conditions After Aortic Valve Replacement for Aortic Stenosis , 2008, Circulation.

[25]  John A Kellum,et al.  Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury , 2007, Critical care.

[26]  A. De Gaetano,et al.  Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: A pilot study* , 2006, Critical care medicine.

[27]  M. Singer,et al.  Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression , 2006, Intensive Care Medicine.

[28]  J. Boldt,et al.  Alterations in circulating vasoactive substances in the critically ill —a comparison between survivors and non-survivors , 1995, Intensive Care Medicine.

[29]  S. Adamopoulos,et al.  Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. , 2004, The American journal of cardiology.

[30]  Marti J. Anderson,et al.  Permutation tests for multi-factorial analysis of variance , 2003 .

[31]  P. Pentikäinen,et al.  Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. , 2002, International journal of clinical pharmacology and therapeutics.

[32]  J. Vincent,et al.  Serial evaluation of the SOFA score to predict outcome in critically ill patients. , 2001, JAMA.

[33]  K. Någren,et al.  Myocardial efficiency during calcium sensitization with levosimendan: A noninvasive study with positron emission tomography and echocardiography in healthy volunteers , 1997, Clinical pharmacology and therapeutics.